Results 171 to 180 of about 3,116,614 (307)

Pharmacological Inhibition of APT2 by Solasonine Promotes Ferroptosis Through Palmitoylation Modulation in Gallbladder Cancer

Phytotherapy Research, EarlyView.
Schematic illustration of SS‐induced ferroptosis through targeting APT2‐mediated STAT3 palmitoylation in GBC cells. ABSTRACT Gallbladder cancer (GBC), the most prevalent and lethal biliary tract malignancy, lacks effective therapeutic strategies. Solasonine (SS), a bioactive steroidal alkaloid derived from Solanum nigrum L, exhibits antitumor activity ...
Liu‐qing Shi, Jing‐wei Zhao, Jia‐yun Zhu, Cheng Zhao, Zi‐yi Yang, Li‐jia Pan, Ben Ma, Zheng‐yu Chen, Zi‐ying Wang, Chun‐jie Li, Shi‐lei Liu, Jia‐wei Mei, Ping Dong   +12 more
wiley   +1 more source

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Sorafenib is an oral multikinase inhibitor that has become an established therapeutic approach in advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib in clinical therapy is often affected by drug resistance.
Qing-Feng Xiang, Mei-Xiao Zhan, Yong Li, Hui Liang, Cong Hu, Yao-Ming Huang, Jing Xiao, Xu He, Yong-Jie Xin, Min-Shan Chen, Li-Gong Lu   +10 more
doaj   +1 more source

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. [PDF]

, 2017
BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type ...
Braiteh, F, Burris, H, Cohn, AL, Foster, P, Kelley, RK, Lee, Y, Spira, A, Su, W-C, Van Cutsem, E, Verslype, C, Vogelzang, N, Yang, T-S   +11 more
core  

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease [PDF]

, 2012
Background The combination of bevacizumab (B) and erlotinib (E) has shown promising clinical outcomes as the first-line treatment of advanced HCC patients.
Chan, P, Cheung, TT, Fan, ST, Pang, R, Poon, RT, Wong, H, Yao, TJ, Yau, T   +7 more
core   +1 more source

A multimodal deep learning framework for predicting sunitinib response in advanced clear cell renal cell carcinoma

VIEW, EarlyView.
In this study, we constructed a prognostic model for ccRCC patients treated with Sunitinib through a deep learning‐based multimodal approach. Our CGPR model further confirms the feasibility of integrating multimodal and provides guidance for future tumor patients to receive precision therapy.
Xi Tian, Yuchen Jiang, Shuxuan Zhu, Xiaohang Liu, Aihetaimujiang Anwaier, Shiqi Ye, Kun Chang, Yuanyuan Qu, Ya‐Jia Gu, Hailiang Zhang, Dingwei Ye, Wenhao Xu   +11 more
wiley   +1 more source

Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. [PDF]

, 2017
Malignant transformation is often accompanied by significant metabolic changes. To identify drivers underlying these changes, we calculated metabolic flux states for the NCI60 cell line collection and correlated the variance between metabolic states of ...
Bordbar, Aarash, Corbett, Austin J, Jamshidi, Neema, Palsson, Bernhard O, Thomas, Alex, Zielinski, Daniel C   +5 more
core   +1 more source

Targeting SPP1‐CD44‐Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis

Cancer Science, EarlyView.
SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara, Shu Shimada, Yoshimitsu Akiyama, Megumi Hatano, Yusuke Chino, Suguru Miyazawa, Hanako Tamura, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Shuichi Watanabe, Eriko Katsuta, Keiichi Akahoshi, Kenichi Ohashi, Minoru Tanabe, Daisuke Ban, Shinji Tanaka   +16 more
wiley   +1 more source

Supplementary Table 2 from Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis [PDF]

, 2023
Alessandro Prete, Agnes S. Lo, Peter M. Sadow, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John G. Clohessy, Ann M. Dvořàk, Tracey Sciuto, Manoj Bhasin, Joanne E. Murphy-Ullrich, Jack Lawler, S. Ananth Karumanchi, Carmelo Nucera   +15 more
openalex   +2 more sources

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources

Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis

Cancer Science, EarlyView.
Using bioinformatic analysis, LCSC models, and transgenic mice, we demonstrate that co‐inhibition of Wnt3a and Loxl2 potently triggers ferroptosis and inhibits orthotopic liver tumorigenesis. The enhanced antitumor effect upon dual targeting, mediated through ZEB1 upregulation, highlights a promising combinatory approach against HCC.
Guanghui Ren, Qingwei Cong, Jing Wang, Wenyue Gao, Yunpeng Guan, Lianxin Zhu, Ying Zhu   +6 more
wiley   +1 more source